Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma, Non-Small-Cell Lung × trilaciclib × Clear all

Phase

Status

Terminated 1 Recruiting 1 Not yet recruiting 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 3 Triple Negative Breast Neoplasms 2 Breast Neoplasms 2 Sarcoma, Ewing 1 Pathologic Complete Response 1 Osteosarcoma 1 Neutropenia 1 Neoplasms 1 Myelosuppression 1 Lung Neoplasms 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 117 Carboplatin 106 Pemetrexed 95 Cisplatin 61 Paclitaxel 48 Drug Therapy 41 osimertinib 40 Nivolumab 40 Docetaxel 38 Specimen Handling 31 Magnetic Resonance Spectroscopy 27 Bevacizumab 26 cemiplimab 22 durvalumab 21 Radiotherapy 20 Gemcitabine 20 130-nm albumin-bound paclitaxel 20 tislelizumab 19 Radiosurgery 18 atezolizumab 17 Immunotherapy 16 Cetuximab 15 aflutinib 14 Ipilimumab 14 Standard of Care 12 Platinum Compounds 12 Immune Checkpoint Inhibitors 12 Surgical Procedures, Operative 11 Blood Specimen Collection 11 Biopsy 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06992739 2026-04-14

PROTECT-2

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡